8 COMPARISON OF THE EFFICACIES OF PROTON PUMP INHIBITORS AND H 2 RECEPTOR ANTAGONISTS IN ON-DEMAND TREATMENT OF GASTROESOPHAGEAL REFLUX DISEASE

No abstract is available for this paper.

• Publication year

  2018

• Venue

  Unknown venue

• Publication date

  Unknown publication date

• Fields of study

  Not labeled

• Identifiers

  No identifiers available.

• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar

• No claims are published for this paper.

• No concepts are published for this paper.

• A randomized open-label trial of on-demand rabeprazole vs ranitidine for patients with non-erosive reflux disease.

  2012cited by this paper
• Response of Regurgitation to Proton Pump Inhibitor Therapy in Clinical Trials of Gastroesophageal Reflux Disease

  2011cited by this paper
• The rate of prescribing gastrointestinal prophylaxis with either a proton pump inhibitor or an H2-receptor antagonist in Nova Scotia seniors starting nonsteroidal anti-inflammatory drug therapy.

  2010cited by this paper
• Safety of the long-term use of proton pump inhibitors.

  2010cited by this paper
• American Gastroenterological Association Institute technical review on the management of gastroesophageal reflux disease.

  2008cited by this paper
• Systematic review: maintenance treatment of gastro‐oesophageal reflux disease with proton pump inhibitors taken ‘on‐demand’

  2007cited by this paper
• On-Demand Therapy for Gastroesophageal Reflux Disease

  2007cited by this paper
• Treatment of Gastroesophageal Reflux Disease*

  2005cited by this paper
• Systematic review: the efficacy of intermittent and on‐demand therapy with histamine H2‐receptor antagonists or proton pump inhibitors for gastro‐oesophageal reflux disease patients

  2005influential reference
• Systematic review: is there excessive use of proton pump inhibitors in gastro‐oesophageal reflux disease?

  2004cited by this paper
• Six‐month trial of on‐demand rabeprazole 10 mg maintains symptom relief in patients with non‐erosive reflux disease

  2004cited by this paper
• On-Demand Therapy with Rabeprazole in Nonerosive and Erosive Gastroesophageal Reflux Disease in Clinical Practice: Effectiveness, Health-Related Quality of Life, and Patient Satisfaction

  2004cited by this paper
• Management of gastroesophageal reflux disease.

  2003cited by this paper
• Esomeprazole 40 mg and 20 mg is efficacious in the long-term management of patients with endoscopy-negative gastro-oesophageal reflux disease: a placebo-controlled trial of on-demand therapy for 6 months

  2002cited by this paper
• Esomeprazole 20 mg maintains symptom control in endoscopy‐negative gastro‐oesophageal reflux disease: a controlled trial of ‘on‐demand’ therapy for 6 months

  2001cited by this paper
• Acid suppression: optimizing therapy for gastroduodenal ulcer healing, gastroesophageal reflux disease, and stress-related erosive syndrome.

  2000cited by this paper
• A cost-effectiveness analysis of prescribing strategies in the management of gastroesophageal reflux disease

  2000cited by this paper
• Onset of action during on‐demand treatment with Maalox suspension or low‐dose ranitidine for heartburn

  1999cited by this paper
• On demand therapy with omeprazole for the long‐term management of patients with heartburn without oesophagitis—a placebo‐controlled randomized trial

  1999cited by this paper
• Gastro‐oesophageal reflux disease in primary care: an international study of different treatment strategies with omeprazole

  1998influential reference
• Gastro-oesophageal reflux disease in primary care: an international study of different treatment strategies with omeprazole. International GORD Study Group.

  1998cited by this paper
• The Impact of Gastroesophageal Reflux Disease on Health-related Quality of Life 1 1 Supported by res

  1998influential reference
• On-demand therapy in gastroesophageal reflux disease: a comparison of the early effects of single doses of fast-dissolving famotidine wafers and ranitidine tablets.

  1997cited by this paper
• Speed of healing and symptom relief in grade II to IV gastroesophageal reflux disease: a meta-analysis.

  1997cited by this paper

• No citing papers are available for this paper.